Proinsulin/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults

Diabetic Medicine

Volumn 28, Issue 2, 2011, Pages 156-161

  Scholin A ^a   Nystrom L ^b   Arnqvist, H ^c   Bolinder, J ^d   Bjork E ^a   Berne, C ^a   Karlsson, F A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

C peptide; Glucagon; Proinsulin; Remission; Type 1 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PROINSULIN;

ADULT; ANTIBODY TITER; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PROTEIN PROCESSING; REMISSION; SEX DIFFERENCE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FASTING; FEMALE; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; MALE; PROINSULIN; PROSPECTIVE STUDIES; REFERENCE VALUES; REMISSION INDUCTION; YOUNG ADULT;

EID: 78651074199     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03191.x     Document Type: Article

References (23)

1. Poitout V, Stein R, Rhodes CJ. Insulin gene expression and biosynthesis. In: DeFronzo RA, Ferrannini E, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus, 3rd edition. Chichester: John Wiley & Sons Ltd., 2004: 97-123.
2. Rhodes CJ, Halban PA. Newly synthesized proinsulin/insulin and stored insulin are released from pancreatic B-cells predominantly via a regulated, rather than a constitutive, pathway. J Cell Biol 1987; 105: 145-153.
3. Letiexhe MR, Scheen AJ, Gerard PL, Bastens BH, Pirotte J, Belaiche J et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab 1993; 77: 1263-1268.
4. Ludvigsson J, Heding L. Abnormal proinsulin/C-peptide ratio in juvenile diabetes. Acta Diabetol Lat 1982; 19: 351-358.
5. Snorgaard O, Hartling SG, Binder C. Proinsulin and C-peptide at onset and during 12 months' cyclosporin treatment of Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 36-42.
6. Bolinder J, Fernlund P, Borg H, Arnqvist HJ, Björk E, Blohmé G et al. Hyperproinsulinemia segregates young adult patients with newly diagnosed autoimmune (Type 1) and non-autoimmune (Type 2) diabetes. Scand J Clin Lab Invest 2005; 65: 585-594.
7. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of Type 2 diabetes. Diabetes 1997; 46: 1725-1732.
8. Laedtke T, Kjems L, Pørksen N, Schmitz O, Veldhuis J, Kao PC et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in Type 2 diabetes. Am J Physiol Endocrinol Metab 2000; 279: E520-E528.
9. Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte D Jr, Robertson RP. Hyperproinsulinemia is associated with increased beta-cell demand after hemipancreatectomy in humans. J Clin Invest 1996; 97: 455-460.
10. Røder ME, Knip M, Hartling SG, Karjalainen J, Akerblom HK, Binder C. Disproportionately elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first-phase insulin responses. The Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab 1994; 79: 1570-1575.
11. Schölin A, Siegbahn A, Lind L, Berne C, Sundkvist G, Björk E et al. CRP and IL-6 concentrations are associated with poor glycaemic control despite preserved beta-cell function during the first year after diagnosis of Type 1 diabetes. Diabetes Metab Res Rev 2004; 20: 205-210.
12. 1c by ion exchange chromatography. Diabetes Care 1996; 19: 142-145.
13. Borg H, Fernlund P, Sundkvist G. Protein tyrosine phosphatase-like protein IA-2 antibodies plus glutamic acid decarbocylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus. Clin Chem 1997; 43: 2358-2363.
14. 35S]GAD 65-ligand binding assay. Clin Chem 1997; 43: 779-785.
15. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836.
16. Petersen KF, Laurent D, Rothman DL, Cline GW, Shulman GI. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 1998; 101: 1203-1209.
17. Pørksen N, Hollingdal M, Juhl C, Butler P, Veldhuis JD, Schmitz O. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes 2002; 51: S245-S254.
18. Hedman CA, Frystyk J, Lindström T, Chen J-W, Flyvbjerg A, Ørskov H et al. Residual beta-cell function more than glycemic control determines abnormalities of the IGF-system in Type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 6305-6309.
19. Zethelius B, Hales CN, Lithell H, Berne C. Insulin resistance, impaired early insulin response, and insulin propeptides as predictors of the development of Type 2 diabetes: a population-based, 7-year follow-up study in 70-year-old men. Diabetes Care 2004; 27: 1433-1438.
20. Björk E, Berne C, Karlsson FA. Induction of β-cell rest in Type 1 diabetes. Studies on the effects of octreotide and diazoxide. Diabetes Care 1998; 21: 427-430.
21. Schölin A, Törn C, Nyström L, Berne C, Arnqvist H, Blohme G et al. Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in Type 1 diabetes. Diabet Med 2004; 21: 447-455.
22. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human Type 1 diabetes. Clin Exp Immunol 2009; 155: 173-181.
23. Meier JJ, Kjems LL, Veldhuis JD, Lefèbvre P, Butler PC. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 2006; 55: 1051-1056.